Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Medicines register
Registers› Irish medicines ›Salofalk 1g/Actuation Rectal Foam
Medicines register · Ireland

Salofalk 1g/Actuation Rectal Foam

Authorisation PA0573/004/005 · Dr. Falk Pharma GmbH

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 19 Nov 2026
Licence holder
Dr. Falk Pharma GmbH (all products →)
Active substance
Mesalazine
Clinical trials
5 clinical trials →
Dosage form
Rectal foam
Route of administration
Rectal use
ATC codes
A07EC, A07EC02
First authorised
09/01/2009
Prescription status
Product subject to prescription which may be renewed (B)
Supply
Supply through pharmacies only
Legal basis
Hybrid application (Article 10(3) of Directive No 2001/83/EC)

Mesalazine: supply and approvals

43 authorised products on the HPRA list contain Mesalazine. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 18 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 18 Nov 2026)
Germany (BfArM)
2 supply notices, e.g. Claversal Micropellets 1,5 g (5 Nov 2025 to 16 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 17 years (since 9 January 2009). The HPRA list marks it as marketed in Ireland.

Other medicines with Mesalazine in Ireland

42 other products on the HPRA list contain Mesalazine, from 9 licence holders; 20 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Asacolon 1000 mg SuppositoryTillotts Pharma GmbHNational authorisation (PA)Marketed
Asacolon 1600 mg modified-release tabletsTillotts Pharma GmbHNational authorisation (PA)Marketed
Asacolon 400mg Gastro-Resistant TabletsTillotts Pharma GmbHNational authorisation (PA)Marketed
Asacolon 500 mg SuppositoriesTillotts Pharma GmbHNational authorisation (PA)Marketed
Asacolon 800mg Gastro-resistant TabletsTillotts Pharma GmbHNational authorisation (PA)Marketed
Mezavant XL 1200 mg gastro-resistant, prolonged release tabletsTakeda Pharmaceuticals International AG Ireland BranchNational authorisation (PA)Marketed
Pentasa 1 g prolonged-release tabletsFerring Ireland LtdNational authorisation (PA)Marketed
Pentasa 10 mg/ml Rectal SuspensionFerring Ireland LtdNational authorisation (PA)Marketed
Pentasa 1g SuppositoriesFerring Ireland LtdNational authorisation (PA)Marketed
Pentasa 500 mg prolonged-release tabletsFerring Ireland LtdNational authorisation (PA)Marketed
Pentasa Sachet 1g prolonged-release granulesFerring Ireland LtdNational authorisation (PA)Marketed
Pentasa Sachet 2g prolonged-release granulesFerring Ireland LtdNational authorisation (PA)Marketed

All 43 products with Mesalazine →

Other substances in ATC group A07EC

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 2 other active substances share the group A07EC with this product:

Sulfasalazine (3) · Olsalazine sodium (2)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Dr. Falk Pharma GmbH holds 18 products on the HPRA list, with 3 different active substances; 14 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 19 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.